Centers for Disease Control and Prevention. National diabetes statistics report, 2020: estimates of diabetes and its burden in the United States. (2020). Accessed 30 Nov 2023. https://www.cdc.gov/diabetes/data/statistics-report/index.html

Cheng YJ, et al. Trends and disparities in cardiovascular mortality among U.S. Adults with and without self-reported diabetes, 1988–2015. Diabetes Care. 2018;41:2306–15. https://doi.org/10.2337/dc18-0831(2018).

Article  PubMed  Google Scholar 

Virani SS, et al. Heart disease and stroke statistics-2020 update: A report from the American Heart Association. Circulation. 2020;141:e139–596. https://doi.org/10.1161/CIR.0000000000000757.

Article  PubMed  Google Scholar 

Rawshani A, et al. Risk factors, mortality, and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2018;379:633–44. https://doi.org/10.1056/NEJMoa1800256.

Article  PubMed  Google Scholar 

Rawshani A, et al. Mortality and cardiovascular disease in type 1 and type 2 diabetes. N Engl J Med. 2017;376:1407–18. https://doi.org/10.1056/NEJMoa1608664.

Article  PubMed  Google Scholar 

Centers for Disease Control and Prevention. Chronic kidney disease surveillance system-United States. https://nccd.cdc.gov/CKD/. Assessed 4 Feb 2024.

Kidney Disease: Improving Global Outcomes Diabetes Work Group. KDIGO 2020 clinical practice guideline for diabetes management in chronic kidney disease. Kidney Int. 2022;98:S1–115.

Google Scholar 

Saran R, et al. US renal data system 2016 annual data report: epidemiology of kidney disease in the United States. Am J Kidney Dis. 2017;69:A7–8. https://doi.org/10.1053/j.ajkd.2016.12.004.

Article  PubMed  PubMed Central  Google Scholar 

Fox CS, et al. Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis. Lancet. 2012;380:1662–73. https://doi.org/10.1016/S0140-6736(12)61350-6.

Article  PubMed  PubMed Central  Google Scholar 

Dalrymple LS, et al. Chronic kidney disease and the risk of end-stage renal disease versus death. J Gen Intern Med. 2011;26:379–85. https://doi.org/10.1007/s11606-010-1511-x.

Article  PubMed  Google Scholar 

Andary R, Fan W, Wong ND. Control of cardiovascular risk factors among us adults with type 2 diabetes with and without cardiovascular disease. Am J Cardiol. 2019;124:522–7. https://doi.org/10.1016/j.amjcard.2019.05.035.

Article  PubMed  Google Scholar 

•• Gaede P, et al. Years of life gained by multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: 21 years follow-up on the Steno-2 randomised trial. Diabetologia. 2016;59:2298–307. https://doi.org/10.1007/s00125-016-4065-6. STENO-2 is the only large prospective multifactorial intervention study comparing intensified versus conventional treatment of modifiable risk factors in patients with type 2 diabetes. The absolute risk reduction in the intensive versus conventionally treated group was 20%.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gaede P, et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med. 2003;348:383–93. https://doi.org/10.1056/NEJMoa021778.

Article  PubMed  Google Scholar 

Mogensen CE. Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes. N Engl J Med. 1984;310:356–60. https://doi.org/10.1056/NEJM198402093100605.

Article  CAS  PubMed  Google Scholar 

Joseph JJ, Deedwania P, Acharya T, Aguilar D, Bhatt DL, Chyun DA, Di Palo KE, Golden SH, Sperling LS, American Heart Association Diabetes Committee of the Council on Lifestyle and Cardiometabolic Health, Council on Arteriosclerosis, Thrombosis and Vascular Biology; Council on Clinical Cardiology; and Council on Hypertension. Comprehensive management of cardiovascular risk factors for adults with type 2 diabetes: a scientific statement from the American Heart Association. Circulation. 2022;145:e722–59. https://doi.org/10.1161/CIR.0000000000001040.

Article  PubMed  Google Scholar 

ElSayed NA, et al. 10. Cardiovascular disease and risk management: standards of care in diabetes-2023. Diabetes Care. 2023;46:S158–90. https://doi.org/10.2337/dc23-S010.

Article  CAS  PubMed  Google Scholar 

Group SR, et al. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med. 2015;373:2103–16. https://doi.org/10.1056/NEJMoa1511939.

Article  CAS  Google Scholar 

Xie X, et al. Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis. Lancet. 2016;387:435–43. https://doi.org/10.1016/S0140-6736(15)00805-3.

Article  PubMed  Google Scholar 

Whelton PK, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American college of cardiology/American heart association task force on clinical practice guidelines. J Am Coll Cardiol. 2018;71:e127–248. https://doi.org/10.1016/j.jacc.2017.11.006.

Article  PubMed  Google Scholar 

Group AS, et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med. 2010;362:1575–85. https://doi.org/10.1056/NEJMoa1001286.

Article  CAS  Google Scholar 

Grundy SM, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American college of cardiology/American heart association task force on clinical practice guidelines. J Am Coll Cardiol. 2019;73:e285–350. https://doi.org/10.1016/j.jacc.2018.11.003.

Article  PubMed  Google Scholar 

Garber AJ, et al. Consensus statement by the American association of clinical endocrinologists and American college of endocrinology on the comprehensive type 2 diabetes management algorithm - 2020 executive summary. Endocr Pract. 2020;26:107–39. https://doi.org/10.4158/CS-2019-0472.

Article  PubMed  Google Scholar 

Goldberg RB, Stone NJ, Grundy SM. The 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guidelines on the management of blood cholesterol in diabetes. Diabetes Care. 2020;43:1673–8. https://doi.org/10.2337/dci19-0036.

Article  PubMed  Google Scholar 

Mach F, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41:111–88. https://doi.org/10.1093/eurheartj/ehz455.

Article  PubMed  Google Scholar 

Sabatine MS, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376:1713–22. https://doi.org/10.1056/NEJMoa1615664.

Article  CAS  PubMed  Google Scholar 

Keech A, et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet. 2005;366:1849–61. https://doi.org/10.1016/S0140-6736(05)67667-2.

Article  CAS  PubMed  Google Scholar 

Keene D, Price C, Shun-Shin MJ, Francis DP. Effect on cardiovascular risk of high density lipoprotein targeted drug treatments niacin, fibrates, and CETP inhibitors: meta-analysis of randomised controlled trials including 117,411 patients. BMJ. 2014;349:g4379. https://doi.org/10.1136/bmj.g4379.

Article  CAS  PubMed  PubMed Central  Google Scholar 

O’Donoghue ML, et al. Small interfering RNA to reduce lipoprotein(a) in cardiovascular disease. N Engl J Med. 2022;387:1855–64. https://doi.org/10.1056/NEJMoa2211023.

Article  CAS  PubMed  Google Scholar 

Nurmohamed NS, Navar AM, Kastelein JJP. New and emerging therapies for reduction of LDL-cholesterol and apolipoprotein B: JACC focus seminar 1/4. J Am Coll Cardiol. 2021;77:1564–75. https://doi.org/10.1016/j.jacc.2020.11.079.

Article  CAS  PubMed  Google Scholar 

Bhatt DL, et al. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. N Engl J Med. 2019;380:11–22. https://doi.org/10.1056/NEJMoa1812792.

Article  CAS  PubMed  Google Scholar 

Rossello X, et al. Glycated hemoglobin and subclinical atherosclerosis in people without diabetes. J Am Coll Cardiol. 2021;77:2777–91. https://doi.org/10.1016/j.jacc.2021.03.335.

Article  PubMed  Google Scholar 

Bancks MP, et al. Long-term absolute risk for cardiovascular disease stratified by fasting glucose level. Diabetes Care. 2019;42:457–65. https://doi.org/10.2337/dc18-1773.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Stratton IM, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321:405–12. https://doi.org/10.1136/bmj.321.7258.405.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Raghavan S, et al. Diabetes mellitus-related all-cause and cardiovascular mortality in a national cohort of adults. J Am Heart Assoc. 2019;8:e011295. https://doi.org/10.1161/JAHA.118.011295.

Article  PubMed  PubMed Central  Google Scholar 

• DeFronzo RA. Insulin resistance, lipotoxicity, type 2 diabetes and atherosclerosis: the missing links. The Claude Bernard Lecture 2009. Diabetologia. 2010;53:1270–87. https://doi.org/10.1007/s00125-010-1684-1. Classic review demonstrating that the molecular etiology of the insulin resistance directly promotes atherogenesis in diabetic, as was in nondiabetic individuals.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tsao CW, et al. Heart disease and stroke statistics-2022 update: a report from the American heart association. Circulation. 2022;145:e153–639. https://doi.org/10.1161/CIR.0000000000001052.

Article  PubMed  Google Scholar 

Ford ES, Williamson DF, Liu S. Weight change and diabetes incidence: findings from a national cohort of US adults. Am J Epidemiol. 1997;146:214–22. https://doi.org/10.1093/oxfordjournals.aje.a009256.

Article